200 related articles for article (PubMed ID: 2714071)
1. Effectiveness of cefotaxime alone and in combination with desacetylcefotaxime against Bacteroides fragilis.
Wasilauskas BL
Diagn Microbiol Infect Dis; 1989; 12(1):39-43. PubMed ID: 2714071
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activity of cefoxitin, cefotaxime alone, and in combination with desacetylcefotaxime against the Bacteroides species.
Canawati HN
Diagn Microbiol Infect Dis; 1989; 12(1):33-7. PubMed ID: 2714070
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the in vitro action and interaction of cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides spp.
Aldridge KE
Diagn Microbiol Infect Dis; 1989; 12(1):45-50. PubMed ID: 2714072
[TBL] [Abstract][Full Text] [Related]
4. The activity of cefotaxime and desacetylcefotaxime alone and in combination against anaerobes and staphylococci.
Jones RN; Barry AL; Packer RR
Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):37S-46S. PubMed ID: 6086217
[TBL] [Abstract][Full Text] [Related]
5. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the bactericidal activity of cefotaxime and desacetylcefotaxime alone and in combination against Bacteroides fragilis group organisms.
Aldridge KE; Weeks LS; Stratton CW; Sanders CV
Diagn Microbiol Infect Dis; 1989; 12(2):165-70. PubMed ID: 2752714
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activity of cefotaxime and desacetylcefotaxime against the Bacteroides fragilis group.
Cornick NA; Gorbach SL
Diagn Microbiol Infect Dis; 1988 Jun; 10(2):81-4. PubMed ID: 3224498
[TBL] [Abstract][Full Text] [Related]
8. In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents.
Aldridge KE; Henderberg A; Sanders CV
J Antimicrob Chemother; 1990 Sep; 26(3):353-9. PubMed ID: 2228826
[TBL] [Abstract][Full Text] [Related]
9. [In vitro synergy between cefotaxime and its main metabolite, desacetylcefotaxime].
Kobayashi S; Arai S; Hayashi S; Sakaguchi T; Kawana R
Jpn J Antibiot; 1988 May; 41(5):594-601. PubMed ID: 3216482
[TBL] [Abstract][Full Text] [Related]
10. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.
Goldstein EJ; Citron DM
J Clin Microbiol; 1988 Nov; 26(11):2361-6. PubMed ID: 3235664
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
Brook I
J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
[TBL] [Abstract][Full Text] [Related]
12. Survey of Bacteroides fragilis group susceptibility patterns in Canada.
Bourgault AM; Lamothe F; Hoban DJ; Dalton MT; Kibsey PC; Harding G; Smith JA; Low DE; Gilbert H
Antimicrob Agents Chemother; 1992 Feb; 36(2):343-7. PubMed ID: 1605600
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of clinical isolates of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan.
Watanabe K; Ueno K; Kato N; Muto Y; Bandoh K; Tanaka Y; Jotwani R; Goto M; Shimada K; Shimizu K
Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1069-73. PubMed ID: 1295761
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the bactericidal activity of clindamycin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
Stratton CW; Weeks LS; Aldridge KE
Diagn Microbiol Infect Dis; 1991; 14(5):377-82. PubMed ID: 1797454
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the pharmacodynamic activity of cefotaxime plus metronidazole with cefoxitin and ampicillin plus sulbactam.
Sullivan MC; Nightingale CH; Quintiliani R; Sweeney KR
Pharmacotherapy; 1995; 15(4):479-86. PubMed ID: 7479201
[TBL] [Abstract][Full Text] [Related]
17. In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents.
Betriu C; Sánchez A; Gómez M; Palau ML; Picazo JJ
J Antimicrob Chemother; 1999 Jan; 43(1):133-6. PubMed ID: 10381111
[TBL] [Abstract][Full Text] [Related]
18. Bactericidal activity of ceftizoxime, cefotetan, and clindamycin against cefoxitin-resistant strains of the Bacteroides fragilis group.
Aldridge KE; Stratton CW
J Antimicrob Chemother; 1991 Nov; 28(5):701-5. PubMed ID: 1778873
[TBL] [Abstract][Full Text] [Related]
19. Activity of cefotaxime/desacetylcefotaxime with two aminoglycosides against gram-negative pathogens: an example of interactive synergy.
Jenkins SG
Diagn Microbiol Infect Dis; 1989; 12(1):51-5. PubMed ID: 2714073
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal study of susceptibilities of species of the Bacteroides fragilis group to five antimicrobial agents in three medical centers.
Turgeon P; Turgeon V; Gourdeau M; Dubois J; Lamothe F
Antimicrob Agents Chemother; 1994 Oct; 38(10):2276-9. PubMed ID: 7840557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
